Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 92

1.

Dose-dense nonpegylated liposomal Doxorubicin and docetaxel combination in breast cancer: dose-finding study.

Ricevuto E, Cocciolone V, Mancini M, Cannita K, Romano S, Bruera G, Pelliccione M, Adinolfi MI, Ciccozzi A, Bafile A, Penco M, Ficorella C.

Oncologist. 2015 Feb;20(2):109-10. doi: 10.1634/theoncologist.2014-0129. Epub 2015 Jan 19.

2.

The prevalent KRAS exon 2 c.35 G>A mutation in metastatic colorectal cancer patients: A biomarker of worse prognosis and potential benefit of bevacizumab-containing intensive regimens?

Bruera G, Cannita K, Tessitore A, Russo A, Alesse E, Ficorella C, Ricevuto E.

Crit Rev Oncol Hematol. 2015 Mar;93(3):190-202. doi: 10.1016/j.critrevonc.2014.10.004. Epub 2014 Oct 16. Review.

PMID:
25459669
3.

Bioclinical parameters driving decision-making of subsequent lines of treatment in metastatic castration-resistant prostate cancer.

Irelli A, Bruera G, Cannita K, Palluzzi E, Gravina GL, Festuccia C, Ficorella C, Ricevuto E.

Biomed Res Int. 2014;2014:909623. doi: 10.1155/2014/909623. Epub 2014 May 28.

4.

Multidisciplinary management of hepatocellular carcinoma in clinical practice.

Bruera G, Cannita K, Giordano AV, Manetta R, Vicentini R, Carducci S, Saltarelli P, Iapadre N, Coletti G, Ficorella C, Ricevuto E.

Biomed Res Int. 2014;2014:806391. doi: 10.1155/2014/806391. Epub 2014 May 8.

5.

Prognostic relevance of KRAS genotype in metastatic colorectal cancer patients unfit for FIr-B/FOx intensive regimen.

Bruera G, Cannita K, Giordano AV, Vicentini R, Ficorella C, Ricevuto E.

Int J Oncol. 2014 Jun;44(6):1820-30. doi: 10.3892/ijo.2014.2369. Epub 2014 Apr 4.

6.

Trifluoroibuprofen inhibits α-methylacyl coenzyme A racemase (AMACR/P504S), reduces cancer cell proliferation and inhibits in vivo tumor growth in aggressive prostate cancer models.

Festuccia C, Gravina GL, Mancini A, Muzi P, Cesare ED, Kirk R, Smith M, Hughes S, Gibson R, Lian LY, Ricevuto E, Carnell AJ.

Anticancer Agents Med Chem. 2014;14(7):1031-41.

PMID:
24712326
7.

Effectiveness and safety of intensive triplet chemotherapy plus bevacizumab, FIr-B/FOx, in young-elderly metastatic colorectal cancer patients.

Bruera G, Cannita K, Giordano AV, Vicentini R, Ficorella C, Ricevuto E.

Biomed Res Int. 2013;2013:143273. doi: 10.1155/2013/143273. Epub 2013 Nov 6.

8.

Differential prognosis of metastatic colorectal cancer patients post-progression to first-line triplet chemotherapy plus bevacizumab, FIr-B/FOx, according to second-line treatment and KRAS genotype.

Bruera G, Cannita K, Giordano AV, Vicentini R, Ficorella C, Ricevuto E.

Int J Oncol. 2014 Jan;44(1):17-26. doi: 10.3892/ijo.2013.2179. Epub 2013 Nov 15.

9.

Close correlation between MEK/ERK and Aurora-B signaling pathways in sustaining tumorigenic potential and radioresistance of gynecological cancer cell lines.

Marampon F, Gravina GL, Popov VM, Scarsella L, Festuccia C, La Verghetta ME, Parente S, Cerasani M, Bruera G, Ficorella C, Ricevuto E, Tombolini V, Di Cesare E, Zani BM.

Int J Oncol. 2014 Jan;44(1):285-94. doi: 10.3892/ijo.2013.2167. Epub 2013 Nov 5.

PMID:
24189697
10.

Phenotypic characterization of human prostatic stromal cells in primary cultures derived from human tissue samples.

Gravina GL, Mancini A, Ranieri G, Di Pasquale B, Marampon F, Di Clemente L, Ricevuto E, Festuccia C.

Int J Oncol. 2013 Jun;42(6):2116-22. doi: 10.3892/ijo.2013.1892. Epub 2013 Apr 10.

PMID:
23589051
11.

Worse prognosis of KRAS c.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx).

Bruera G, Cannita K, Di Giacomo D, Lamy A, Frébourg T, Sabourin JC, Tosi M, Alesse E, Ficorella C, Ricevuto E.

BMC Med. 2013 Mar 4;11:59. doi: 10.1186/1741-7015-11-59.

12.

Prognostic value of KRAS genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to extension of metastatic disease.

Bruera G, Cannita K, Di Giacomo D, Lamy A, Troncone G, Dal Mas A, Coletti G, Frébourg T, Sabourin JC, Tosi M, Ficorella C, Ricevuto E.

BMC Med. 2012 Nov 8;10:135. doi: 10.1186/1741-7015-10-135.

13.

Increased expression of a set of genes enriched in oxygen binding function discloses a predisposition of breast cancer bone metastases to generate metastasis spread in multiple organs.

Capulli M, Angelucci A, Driouch K, Garcia T, Clement-Lacroix P, Martella F, Ventura L, Bologna M, Flamini S, Moreschini O, Lidereau R, Ricevuto E, Muraca M, Teti A, Rucci N.

J Bone Miner Res. 2012 Nov;27(11):2387-98. doi: 10.1002/jbmr.1686.

PMID:
22714395
14.

Triplet chemotherapy in patients with metastatic colorectal cancer: toward the best way to safely administer a highly active regimen in clinical practice.

Ficorella C, Bruera G, Cannita K, Porzio G, Baldi PL, Tinari N, Natoli C, Ricevuto E.

Clin Colorectal Cancer. 2012 Dec;11(4):229-37. doi: 10.1016/j.clcc.2012.05.001. Epub 2012 Jun 12. Review.

PMID:
22694897
15.

Effectiveness of liver metastasectomies in patients with metastatic colorectal cancer treated with FIr-B/FOx triplet chemotherapy plus bevacizumab.

Bruera G, Cannita K, Giuliante F, Lanfiuti Baldi P, Vicentini R, Marchetti P, Nuzzo G, Antonucci A, Ficorella C, Ricevuto E.

Clin Colorectal Cancer. 2012 Jun;11(2):119-26. doi: 10.1016/j.clcc.2011.11.002. Epub 2011 Dec 27.

PMID:
22206922
16.

Differential effects of PXD101 (belinostat) on androgen-dependent and androgen-independent prostate cancer models.

Gravina GL, Marampon F, Giusti I, Carosa E, Di Sante S, Ricevuto E, Dolo V, Tombolini V, Jannini EA, Festuccia C.

Int J Oncol. 2012 Mar;40(3):711-20. doi: 10.3892/ijo.2011.1270. Epub 2011 Nov 23.

PMID:
22134754
17.

Serial measurements of NT-proBNP are predictive of not-high-dose anthracycline cardiotoxicity in breast cancer patients.

Romano S, Fratini S, Ricevuto E, Procaccini V, Stifano G, Mancini M, Di Mauro M, Ficorella C, Penco M.

Br J Cancer. 2011 Nov 22;105(11):1663-8. doi: 10.1038/bjc.2011.439. Epub 2011 Nov 8.

18.

Modulation of GemOx chemotherapy according to CIRS in elderly patients with advanced pancreatic cancer.

Tudini M, Palluzzi E, Cannita K, Mancini M, Santomaggio A, Bruera G, Baldi PL, Pelliccione M, Ricevuto E, Ficorella C.

Oncol Rep. 2012 Feb;27(2):423-32. doi: 10.3892/or.2011.1517. Epub 2011 Oct 21.

PMID:
22020810
19.

Home care for cancer patients after an earthquake: the experience of the "L'Aquila per la Vita" Home Care Unit.

Porzio G, Aielli F, Verna L, Aloisi P, Guadalupi F, Cannita K, Ricevuto E, Ficorella C.

J Pain Symptom Manage. 2011 Sep;42(3):e1-4. doi: 10.1016/j.jpainsymman.2011.06.004. No abstract available.

PMID:
21854991
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk